Research and Markets – Cytokine-Based Research Continues to Revolutionise the Treatment of Inflammatory, Infectious, and Neoplastic Diseases

(PRWEB) November 15, 2004

Research and Markets ( has announced the addition of Cytokines, Chemokines, and Growth Factors- Key Targets for Immunotherapeutic Development to their offering.

The cytokines, chemokines, and growth factors market has $ 90 billion revenue potential. Cytokine-based research is revolutionizing the treatment of inflammatory, infectious, and neoplastic diseases. Many of the original cytokine treatments (i.e. interferon-1beta, and Tnf-alpha) have given way to more refined approaches as the knowledge and discovery process concerning complex cytokine and chemokine networks becomes further clarified. The increased market penetration of approved drugs targeting cytokines and their receptors has spurred several pharmaceutical companies to devote a portion of their pipelines to the development of these immunotherapeutics.

The Cytokines, Chemokines, and Growth Factors Market Analysis Report provides a thorough review of this promising drug target class.

This Report will help:

Pinpoint the full market potential of cytokine- and chemokine-based drugs with an examination of the projected market impact through 2009.

Identify commercial opportunities for immunotherapeutic drug technologies via a thorough assessment of current and emerging drug development platforms, including particular immunodiagnostics utilized to discover novel cytokine drugs.

Discover what’s new in the industry with a comprehensive update and discussion of novel cytokine, chemokine and growth factor classification and nomenclature schemes.

Obtain a complete and extensive appraisal of the development status for all cytokine-based drugs and clinical trials of all phases, including pre-clinical studies, via a meta-analysis of each disease application and investigated cytokine.

Get an up-to-date review of pathogenic cytokine findings through an evaluation of the latest developments critical to novel cytokine-based products and clinical trials, including a prodigious list of references and key Web site links.

Identify trends in each of the immunotherapeutic sub-sectors with an in-depth review of monoclonals, receptor antagonists, small molecule growth factors, signal cascades, ex vivo cell transfer, and gene therapy

Learn about the current patent and licensing landscape of immunotherapeutics from a critical evaluation of patent issues, licensing agreements, and partnerships of immunotherapeutic companies, including associated marketing profiles of major immunotherapeutic/biologicals companies.

Look inside 70 companies utilizing cytokines and chemokines for drug development, including their product pipelines, financial standing, partnerships and alliances, and more.

This Report will benefit the following professionals involved in immunotherapeutics, biologics, and immunodiagnostics:

Presidents, Vice Presidents, Marketing Directors, Clinical Trial Directors, Research Managers, Senior Scientists, and other major decision-makers.

Chapters provided include:

-Opportunities for Drug Development

Cytokine Classification and Nomenclature

Cytokine-Associated Clinical Pathologies and Current Research I. Autoimmunity and Allergy

-Cytokine-Associated Clinical Pathologies and Current Research II. Oncology

-Cytokine-Associated Clinical Pathologies and Current Research III. Infection and Wound Healing

Cytokine-Based and -Modifying Immunotherapeutic Biologicals, Drugs, Vaccines, and Gene Therapy

-Cytokine Immunotherapeutics Companies: Profiles, Finances, and Partnerships

Abbott Laboratories

Abgenix, Inc.

Advanced Biotherapy, Inc.

Amarillo Biosciences, Inc.

Amgen, Inc.

Amrad Corporation, Ltd.

AnGes MG, Inc.

Applied Molecular Evolution, Inc.

Avanir Pharmaceuticals, Inc.

Avant Immunotherapeutics, Inc.

Biogen, Inc.

Biomira, Inc.

BioVex, Ltd

Boston Life Sciences, Inc.

Cambridge Antibody Technology Group plc

Celgene Corp. (Signal Pharmaceuticals)

Celltech Group plc

Centocor, Inc. (Johnson & Johnson)

Cephalon, Inc.

ChemoCentryx, Inc

Chemokine Therapeutics Corp.

Chiron Corp.

Chugai Pharmaceutical Co. Ltd.

Coley Pharmaceutical Group

Corixa Corp.

Deltagen, Inc.

Enact Pharma plc

Essex Bio-Technology, Ltd.

Genaera Corp.

Genentech, Inc.

GeneTrol Biotherapeutics, Inc.

Genmab A/S

Genzyme Corp.

Guilford Pharmaceuticals, Inc.

Human Genome Sciences, Inc.

ICOS Corporation

ImClone Systems, Inc.

Immuno-Designed Molecules, SA

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Interleukin Genetics, Inc.

Isis Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc

Maxim Pharmaceuticals, Inc.

Medarex, Inc.

MedImmune, Inc.

Millennium Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc

Peregrine Pharmaceuticals, Inc.

Protein Design Labs, Inc.

Protherics plc

Regeneron Pharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc

ReNeuron Holdings plc

Repligen Corp.

SangStat Medical Corp.

Savient Pharmaceuticals, Inc. (Myelos Corp.)

Schering-Plough Corp.

SciClone Pharmaceuticals, Inc.

Serono Inc. (Group)

Sunesis Pharmaceuticals, Inc.

Transgene S.A.

Transition Therapeutics, Inc.

Valentis Inc.

Vertex Pharmaceuticals, Inc.

Virax Holdings, Ltd.

Xenova Group plc

Yamanouchi Pharmaceutical Co. Ltd.

ZymoGenetics, Inc.

For more information visit

Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980


Biological Nomenclature
More Biological Nomenclature Press Releases

Leave a Reply